In our study, we discovered that CAP prevented the HFD-induced upregulation of CB1 receptor expression because HU-210 treatment of the HFD+C group partially abolished the beneficial effects of dietary CAP on gut barrier, metabolic endotoxemia, and CLGI, indicating that CB1 inhibition also partially contributes to the anti-obesity effects of CAP. Here, CNR1 is linked to obesity disorder.